BiotechTube

KT-621

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atopic Dermatitis

Conditions

Atopic Dermatitis

Trial Timeline

Nov 24, 2025 → Jun 1, 2028

NCT ID
NCT07217015

About KT-621

KT-621 is a phase 2 stage product being developed by Kymera Therapeutics for Atopic Dermatitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07217015. Target conditions include Atopic Dermatitis.

What happened to similar drugs?

20 of 20 similar drugs in Atopic Dermatitis were approved

Approved (20) Terminated (1) Active (0)
✅LebrikizumabEli LillyApproved
✅tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
✅tacrolimusAstellas PharmaApproved
✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
✅Tacrolimus 0.03% + Fluticasone 0.005%Astellas PharmaApproved
✅Protopic + Corticosteroid + placeboAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT07323654Phase 2Recruiting
NCT07217015Phase 2Recruiting
NCT06945458Phase 1Completed

Competing Products

20 competing products in Atopic Dermatitis

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
40
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
40
LebrikizumabEli LillyApproved
50
LebrikizumabEli LillyPhase 3
40
Lebrikizumab + PlaceboEli LillyPhase 3
44
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
19
LebrikizumabEli LillyPhase 3
40
ASN008Formation BioPhase 2
25
ENS-002Concerto BiosciencesPhase 1
11
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
35
YH35324 + Placebo + OmalizumabYuhanPhase 1
29
YH35324 + Placebo + OmalizumabYuhanPhase 1
29
DS-2741a + PlaceboDaiichi SankyoPhase 1
21
SUN13834 + PlaceboDaiichi SankyoPhase 2
35
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
35
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
35
tacrolimus ointmentAstellas PharmaPhase 3
40
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
43
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
43
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
35